In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|September 19, 2017
Gates Foundation Invests $40 Million in Immunotherapy Collaboration
Author(s)BioPharm International Editors
The collaboration with Immunocore, a T cell receptor company, aims to discover and develop immunotherapy molecules to treat infectious diseases.
Advertisement
The Bill & Melinda Gates Foundation will invest up to $40 million in a collaboration with Immunocore, a T cell receptor (TCR) company developing biological drugs to treat cancer, infectious diseases, and autoimmune diseases. The investment will support the development of Immunocore’s soluble TCR-based therapeutics for infectious diseases, Immunocore announced on Sep. 18, 2017.
The development includes Immunocore’s ImmTAV (immune mobilizing monoclonal TCRs against virus) and ImmTAB (immune mobilizing monoclonal TCRs against bacteria) therapeutics for infectious diseases. The collaboration will discover and develop ImmTAV and ImmTAB molecules to treat tuberculosis (TB) and human immunodeficiency virus (HIV) where the TCR-based therapeutics have the potential to reduce treatment timelines and improve patient outcomes. Immunocore will also continue expanding its platform technology to enable therapeutics with broad coverage of the affected disease population.
This new collaboration is part of a larger initiative within Immunocore to apply its soluble TCR-based therapeutics to areas outside of oncology, including infectious diseases and autoimmune diseases. The company’s published preclinical data demonstrated the potential of ImmTAV molecules to redirect the immune system to kill HIV-infected cells from patients treated with antiretroviral therapy, facilitating the clearance of reactivated, latently infected HIV reservoir cells. These data, coupled with the clinical efficacy and safety profile emerging from the company’s lead program in oncology, set the foundation for the application of the company’s platform technology across multiple diseases.
“We believe the immune system harbors the capacity to resolve problematic infectious diseases and our TCR based therapies are well placed to mobilize this process. Our purpose in the Immunocore infectious disease unit is to revolutionize treatments for diseases such as hepatitis B, tuberculosis, and HIV and provide affordable medicines globally including in the developing world. This collaboration will be critical to this initiative,” said Namir Hassan, vice president of the infectious disease unit at Immunocore, in a company press release.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5